Chardan Capital Has Strong Estimate for SLDB FY2025 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Investment analysts at Chardan Capital lifted their FY2025 earnings per share estimates for shares of Solid Biosciences in a research report issued on Wednesday, February 19th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings per share of ($1.82) for the year, up from their previous forecast of ($2.03). Chardan Capital currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share.

Several other brokerages have also recently weighed in on SLDB. Citizens Jmp raised shares of Solid Biosciences to a “strong-buy” rating in a research report on Tuesday, December 10th. JPMorgan Chase & Co. cut their price objective on shares of Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. Truist Financial started coverage on shares of Solid Biosciences in a research report on Wednesday, January 8th. They set a “buy” rating and a $16.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a report on Friday, January 10th. Finally, JMP Securities initiated coverage on shares of Solid Biosciences in a research note on Tuesday, December 10th. They issued an “outperform” rating and a $15.00 price objective for the company. Nine analysts have rated the stock with a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $15.40.

Solid Biosciences Trading Down 5.2 %

Solid Biosciences stock opened at $5.29 on Monday. The firm’s fifty day moving average price is $3.86 and its two-hundred day moving average price is $5.71. The firm has a market capitalization of $214.66 million, a price-to-earnings ratio of -1.74 and a beta of 2.01. Solid Biosciences has a 1-year low of $2.88 and a 1-year high of $15.05.

Institutional Investors Weigh In On Solid Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. purchased a new position in shares of Solid Biosciences during the 4th quarter valued at $34,000. Corton Capital Inc. purchased a new position in Solid Biosciences during the fourth quarter worth about $41,000. Invesco Ltd. bought a new position in Solid Biosciences in the 4th quarter worth about $49,000. Sei Investments Co. purchased a new stake in shares of Solid Biosciences in the 4th quarter valued at about $52,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Solid Biosciences by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 13,138 shares of the company’s stock valued at $53,000 after acquiring an additional 2,986 shares in the last quarter. 81.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Solid Biosciences news, CEO Alexander Cumbo sold 11,114 shares of the stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total transaction of $62,238.40. Following the sale, the chief executive officer now owns 38,484 shares in the company, valued at $215,510.40. This represents a 22.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jessie Hanrahan sold 4,610 shares of Solid Biosciences stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $25,816.00. Following the completion of the transaction, the insider now owns 14,235 shares of the company’s stock, valued at approximately $79,716. This trade represents a 24.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,069 shares of company stock worth $137,301 over the last quarter. 13.63% of the stock is currently owned by company insiders.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.